BRIDGE: Maintenance of Platelet inihiBition With cangRelor After dIscontinuation of ThienopyriDines in Patients Undergoing surGEry.
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2016
At a glance
- Drugs Cangrelor (Primary)
- Indications Coronary thrombosis
- Focus Registrational; Therapeutic Use
- Acronyms BRIDGE
- Sponsors The Medicines Company
- 14 Nov 2014 The Medicines Company plans to resubmit an NDA for cangrelor by the end of 2014 with respect to the PCI indication, according to a media release.
- 14 Nov 2014 The NDA filing was based on data from the CHAMPION PHOENIX, CHAMPION PLATFORM, CHAMPION PCI, and BRIDGE, according to a media release from the The Medicines Company.
- 18 Jan 2012 Primary endpoint 'Platelet-aggregation' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History